

## REMARKS

Applicants, pursuant to the Examiner's instructions in the **Notice of Non-Compliant Amendment** mailed March 1, 2010, respectfully resubmit the amendments to the specification filed on August 11, 2009 and December 8, 2009 in the instant application. In addition, Applicants have corrected grammatical errors. Specifically, page 11, lines 14, 16, 18, 20, 22, and 25 of the specification are amended to change "**sequences**" to "**sequence.**" Page 11, line 29 is amended to change "**acids**" to "**acid.**" These amendments to the specification have been made to the version of the specification filed on June 1, 2006 and correctly indicate text to be deleted as ~~struck through~~ and replacement text as underlined.

No new matter is added by virtue of these amendments.

Applicant believes that all objections raised in the Office Action mailed March 1, 2010 in connection with the instant application have now been addressed.

Pursuant to a telephone conversation with Primary Examiner Bridget Bunner on March 23, 2010, the following have been made of record and need not be resubmitted with this response: (1) Applicants' arguments/remarks filed August 11, 2009; (2) Replacement Sheet for Figures 1 and 2; (3) Marked up Copy of Figure 1; (4) Exhibit A; (5) Exhibit B; (6) Replacement Sequence Listing and Accompanying Statement; (7) Petition for a 3 month extension of time under 37 CFR § 1.136; and, (8) the fee set in 37 CFR § 1.17(a).

Although no additional fees are believed to be due at this time, the Commissioner is authorized to charge any necessary fees or other relief that may be required, or credit any overpayment to Facet Biotech Corporation, Deposit Account No. 50-4820 (**Order No. 116 US PC02**).

Respectfully submitted,

Date:

*March 30, 2010*  
Facet Biotech Corporation  
Customer No. 84560  
Telephone: 650.454.2338  
Facsimile: 650.454.1468

*Rence M. Kosslak*  
Rence M. Kosslak  
Reg. No. 47,717